251 related articles for article (PubMed ID: 37782910)
1. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
2. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
3. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
4. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
5. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
6. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Itoh M; Kawagoe S; Nakagawa H; Asahina A; Okano HJ
Exp Dermatol; 2023 Feb; 32(2):126-134. PubMed ID: 36222007
[TBL] [Abstract][Full Text] [Related]
7. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
8. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
9. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
van der Stegen SJC; Lindenbergh PL; Petrovic RM; Xie H; Diop MP; Alexeeva V; Shi Y; Mansilla-Soto J; Hamieh M; Eyquem J; Cabriolu A; Wang X; Abujarour R; Lee T; Clarke R; Valamehr B; Themeli M; Riviere I; Sadelain M
Nat Biomed Eng; 2022 Nov; 6(11):1284-1297. PubMed ID: 35941192
[TBL] [Abstract][Full Text] [Related]
10. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
11. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
12. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
Jing R; Scarfo I; Najia MA; Lummertz da Rocha E; Han A; Sanborn M; Bingham T; Kubaczka C; Jha DK; Falchetti M; Schlaeger TM; North TE; Maus MV; Daley GQ
Cell Stem Cell; 2022 Aug; 29(8):1181-1196.e6. PubMed ID: 35931029
[TBL] [Abstract][Full Text] [Related]
13. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
15. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells.
Deng X; Zhou J; Cao Y
Chin Med J (Engl); 2023 Jan; 136(2):127-137. PubMed ID: 36806264
[TBL] [Abstract][Full Text] [Related]
16. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
[TBL] [Abstract][Full Text] [Related]
17. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
[TBL] [Abstract][Full Text] [Related]
18. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
19. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
20. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
Netsrithong R; Wattanapanitch M
Front Immunol; 2021; 12():759558. PubMed ID: 34650571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
